Contineum Therapeutics, Inc. (CTNM)·Q3 2025 Earnings Summary

Executive Summary

• Contineum reported a narrower quarterly loss with EPS of $(0.45), alongside higher R&D and G&A as programs advanced; cash and marketable securities were $182.4M with runway extended to 2028 .
• Guidance and program timelines were maintained for key catalysts: PIPE-307 Phase 2 VISTA topline by Q4 2025 and initiation of PIPE-791 global Phase 2 in IPF in Q4 2025; CTX-343 and PIPE-791 PrMS efforts were deferred to prioritize IPF and extend runway .
• Against S&P Global consensus, EPS essentially matched and revenue missed: EPS actual $(0.45) vs $(0.46); revenue actual $0 vs $5.0M estimate; investors’ focus now shifts to near-term VISTA data and IPF trial start (potential stock catalysts) (estimates from S&P Global).
• Management emphasized disciplined capital allocation and program prioritization, citing the extended runway “through 2028” as enabling execution through multiple inflection points .

What Went Well and What Went Wrong

• What Went Well

  • Cash runway extended to fund planned operations through 2028, driven by program sequencing and ATM proceeds ($19.0M net for ~3.2M shares at a $6.04 WAP) .
  • Positive PIPE-791 Phase 1b PET data demonstrated high brain receptor occupancy with PK-RO correlation, supporting once-daily dosing assumptions heading into Phase 2 .
  • Clear near-term catalysts reiterated: PIPE-307 VISTA topline in Q4 2025; initiation of global IPF Phase 2 in Q4 2025; chronic pain Phase 1b topline in H1 2026 .

• What Went Wrong

  • Operating expenses increased year over year, reflecting higher clinical and personnel costs (R&D +13% YoY to $11.0M; G&A +21% YoY to $3.9M), keeping losses elevated despite lower interest income YoY .
  • Deferral of PIPE-791 PrMS Phase 2 and CTX-343 clinical plans reduces near-term breadth of pipeline readouts outside IPF/RRMS, albeit improving capital runway .
  • Revenue remained at $0; with no product revenues and constrained collaboration revenue recognition, net loss continues (Q3 net loss $12.8M vs $10.3M LY) .

Financial Results

• Consolidated P&L and Cash (oldest → newest)

Notes: Company reports no product revenue and recognized no collaboration revenue in Q3 periods shown . Dashes indicate not explicitly disclosed in the source for that quarter.

• Q3 2025 vs Estimates (S&P Global; actuals company filings)

Values with * are retrieved from S&P Global.

• R&D Program Expense Mix (Q3)

• KPIs

Margins: Net income margin and operating margin are not meaningful due to zero revenue .

Guidance Changes

Earnings Call Themes & Trends

No Q3 2025 earnings call transcript was found in company filings or the document catalog; themes below reflect management’s Q3 press release and 10-Q plus prior-quarter press releases .

Management Commentary

• “We have several important catalysts on the horizon during the next 12 months… topline data from our PIPE-307 Phase 2 VISTA trial… and initiating a comprehensive global Phase 2 [IPF]… chronic pain trial will read out… in the first half of 2026.” — Carmine Stengone, CEO .
• “With a cash runway that is now projected to extend through 2028, we’re fostering a disciplined approach to capital allocation that prioritizes our key programs and clinical development inflection points.” — Peter Slover, CFO .
• “PIPE-791 achieves high, sustained brain RO… unique pharmacological properties… provide a solid foundation for advancing PIPE-791 into Phase 2 trials.” — Timothy Watkins, M.D., M.Sc., CMO .
• “Based on the distribution pattern of PIPE-791, we believe the brain is an appropriate surrogate for predicting RO in the lungs.” — Daniel Lorrain, Ph.D., CSO .

Q&A Highlights

No Q3 2025 earnings call transcript was available in filings or the document catalog; therefore, no Q&A highlights could be extracted. This recap reflects disclosures from the Q3 press release, 10-Q, and related 8-Ks .

Estimates Context

• EPS was essentially in line with consensus: $(0.45) actual vs $(0.46) consensus mean*; six-to-seven estimates on the quarter for EPS (estimates from S&P Global).
• Revenue missed consensus ($0 actual vs $5.0M estimate*), but the company historically recognizes no revenue absent milestones; management explicitly reported no revenue recognition for Q3 periods (estimates from S&P Global).
• Target price consensus mean stood at ~$23.04*; recommendation text not available in the pull (estimates from S&P Global).

Values with * are retrieved from S&P Global.

Key Takeaways for Investors

• Runway extended to 2028 reduces financing overhang near term and supports delivery of multiple data points (RRMS VISTA topline Q4 2025; IPF Phase 2 start Q4 2025; pain Phase 1b topline H1 2026) .
• Positive PET data de-risks PIPE-791 dose selection and supports once-daily IPF Phase 2 design; this, plus VISTA RRMS topline, are the primary catalysts into year-end/early 2026 .
• Operating spend is ramping in line with development progress; watch program-level R&D mix (PIPE-791 costs rising with IPF startup; PIPE-307 costs moderating as VISTA nears topline) .
• Near-term estimate revisions may focus on opex trajectory and timing probabilities for 2025–2026 readouts rather than revenue/EPS, given zero revenue and clinical-stage status .
• Deferrals (PrMS Phase 2, CTX-343) trade breadth for depth and runway; thesis tightens around PIPE-791 (IPF) and PIPE-307 (RRMS/MDD partner-led) .
• ATM usage added ~$19M in Q3 and increased float; monitor future use vs milestones pacing .

---

Sources and citations:

• Q3 2025 8-K press release and exhibits (financial results, guidance and quotes) .
• Q3 2025 10-Q (financial statements, R&D mix, runway detail and MD&A) .
• Q2 2025 8-K press release (milestones, runway, spend) .
• Q1 2025 8-K press release (milestones, runway) .
• PIPE-791 Phase 1b PET topline press release (positive PET data) .

Estimates: Values retrieved from S&P Global.